



ABN 53 075 582 740

ASX ANNOUNCEMENT
29 January 2014

BIONOMICS' ACHIEVEMENTS TO BE SHOWCASED AT AUSTRALASIAN NEUROSCIENCE SOCIETY MEETING

Bionomics Limited (ASX:BNO, ADR:BMICY) will be a major participant at the annual meeting of the Australasian Neuroscience Society (ANS) in Adelaide this week.

The company will present two posters on compounds produced as part of the alpha 7 program while Bionomics' CEO Dr Deborah Rathjen will be speaking as part of a separate satellite meeting for the ANS at the conclusion of the annual event.

The 34th annual meeting runs for four days from 28 January with approximately 800 local and international scientists attending to discuss a wide range of neuroscience related topics including neuro-inflammation, synaptic transmission and drug addiction.

Bionomics' first poster, *Novel positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor demonstrate effective cognitive enhancement in mice and rats*, highlights the superior potency and efficacy of Bionomics' compound BNC375 has shown in animal models.

The company will also present *Identification of type I positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor for the treatment of cognitive impairment in neurodegenerative and psychiatric disease*, where in vivo data has shown pro-cognitive effects in a mouse T-maze continuous alternation task.

Dr Rathjen's presentation, *A local SA success story of Neuropharmacology drug development*, forms part of an ANS satellite meeting on 1 February titled *Brain, Body & Mind: Treating the parts or managing the whole?*

There is a large body of evidence implicating the $\alpha 7$ nAChR in the pathophysiology of several neurodegenerative and neuropsychiatric diseases. Modulation of this receptor enhances cognitive processes, for example attention, which is compromised in these disorders.

BNC375 has a 100-fold therapeutic dose range and has demonstrated a wide safety window in preclinical studies conducted to date. In the animal models BNC375 is benchmarked against Donepezil (Aricept). Aricept, first approved in 1996, is the largest selling drug for treatment of cognitive deficit in Alzheimer's disease.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co and Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.